Skip to main content
. 2020 Dec;19(4):342–369. doi: 10.2174/1871523018666190911121306

Table 3.

Multiple-dose PK of tegaserod.

Treatment
(BID)
Pharmacokinetic Parameters (mean ± SD, median for tmax)
Cmax,ss
(ng/mL)
AUCτ
(ng*h/mL)
tmax,ss
(h)
Cmin,ss
(ng/mL)
Accumulation Ratio
2 mg 0.7 ± 0.3 2.4 ±1.3 1 < LOQ 0.93
6 mg 2.7 ±1.2 8.9 ±4.2 0.8 0.11 ±0.07 1.16
12 mg (2x6 mg) 5.6 ±2.9 20.4 ±14.0 1 0.28 ±0.11 1.15

Data are referred to a study involving 18 subjects (11 male and 7 female) aged 21-36 years [121].